Acrylamide (AA) is a vinyl monomer, from which polyacrylamides are synthesised. It is a colourless and odourless compound widely distributed in the environment, which forms naturally in high-carbohydrate products, mainly potatoes and cereals, when these are subjected to thermal processing at temperatures higher than 120°C (13, 18). It has a fairly well-known biological activity, as indicated by the harmonised classification of this compound (CAS Registry Number 79-06-1). Acrylamide is absorbed into the body through the digestive tract, respiratory system and skin (26).
The first studies on the toxicity of this compound began in the late 1970s and 1980s (3, 10). Since then, numerous studies have confirmed its diverse harmful activities. Yener and Dıkmenlı (22) demonstrated that AA can cause genotoxicity in rats and mice. Research by Manière
Since the discovery of acrylamide’s presence in food, many studies have indicated that this compound participates in the development of neoplasms (14). Despite the association that many studies show between the occurrence of cancer in animals and AA in the diet, none of the studies conducted in humans have clearly demonstrated the direct influence of this compound on the formation of specific types of cancer. However, they undoubtedly indicate that AA is associated with increased cancer frequency.
Due to the lifelong constant exposure of humans and animals to the effects of low doses of acrylamide and despite the availability of extensive toxicological data on the compound, it is reasonable to conduct more research on how strong and diverse the impacts of AA on human and animal organisms really are, and whether exposure to it could be a more serious threat to human and animal health than we currently believe. The research model choice was based on the general recognition that the domestic pig is a scientific model adapted to humans (25).
It is necessary to expand knowledge on the impact of repeated exposure to acrylamide, especially in the aspect of assessing interspecies differences in sensitivity to this xenobiotic, and therefore we decided to evaluate the impact of high and low doses of this compound on the process of granulopoiesis in porcine bone marrow.
Cytological evaluation of bone marrow smears before AA administration (day 0) did not show any significant differences in the number and morphology of all types of cells between all three groups (Table 1).
The average number of cells from the granulocytic cell line per 1,000 porcine bone marrow cells (mean ± SD) before acrylamide administration
Cell type | Control group | Low dose group | High dose group |
---|---|---|---|
Myeloblasts | 2.720 ± 0.504 | 2.980 ± 0.336 | 2.820 ± 0.344 |
Promyelocytes | 2.080 ± 0.656 | 2.160 ± 0.672 | 2.240 ± 0.192 |
Myelocyte | 3.600 ± 0.120 | 3.520 ± 0.144 | 3.200 ± 0.240 |
Metamyelocyte | 6.500 ± 1.000 | 6.360 ± 0.568 | 6.360 ± 0.888 |
Band neutrophils | 15.180 ± 2.584 | 13.620 ± 1.064 | 14.520 ± 1.576 |
Neutrophilic granulocytes | 12.400 ± 2.200 | 13.380 ± 2.224 | 12.820 ± 2.296 |
Eosinophilic myelocytes | 1.740 ± 0.416 | 1.320 ± 0.384 | 1.620 ± 0.264 |
Eosinophilic metamyelocytes | 1.960 ± 0.552 | 2.260 ± 0.568 | 2.200 ± 0.280 |
Band eosinophils | 2.640 ± 1.728 | 2.820 ± 1.624 | 2.780 ± 1.176 |
Eosinophilic granulocytes | 1.300 ± 0.720 | 1.560 ± 1.272 | 1.960 ± 1.632 |
Basophilic myelocytes | 0.000 | 0.000 | 0.000 |
Basophilic metamyelocytes | 0.060 ± 0.048 | 0.020 ± 0.032 | 0.080 ± 0.064 |
Band basophiles | 0.280 ± 0.136 | 0.320 ± 0.184 | 0.375 ± 0.225 |
Basophilic granulocytes | 0.360 ± 0.192 | 0.280 ± 0.136 | 0.300 ± 0.160 |
Hypersegmented granulocytes | 0.000 | 0.000 | 0.000 |
Total granulocytes | 50.820 ± 1.184 | 50.600 ± 2.76 | 51.220 ± 0.896 |
However, there was a significant decrease in the total number of granulocytes in experimental pigs at the end of the experiment (Table 2). The number of myeloblasts, promyelocytes, myelocytes, and basophilic granulocytes declined significantly (P ≤ 0.05) after 28 days of receiving AA (Table 2), the high doses of which affected some cells differently to the low doses. Acrylamide used in low doses decreased the total of neutrophilic granulocytes and band eosinophils. However, used in high doses it increased the numbers of those cells. Basophilic myelocytes appeared only in the control group at the end of the experiment (Fig. 3). Our research also showed very clear changes in the morphology of granulocytes consisting in strong condensation and fragmentation of chromatin in cell nuclei in the HD group (Figs. 1 and 2).
The average number of cells from the granulocytic cell line per 1,000 porcine bone marrow cells (mean ±SD) on the 28th day of the experiment
Cell type | Control group | Low dose group | High dose group |
Myeloblasts | 2.680 ± 0.576 statistically significant difference between control and low dose group (P ≤ 0.05) statistically significant difference between control and high dose group (P ≤ 0.05) |
1.160 ± 0.512 statistically significant difference between control and low dose group (P ≤ 0.05) |
1.080 ± 0.104 statistically significant difference between control and high dose group (P ≤ 0.05) |
Promyelocytes | 2.100 ± 0.68 statistically significant difference between control and low dose group (P ≤ 0.05) statistically significant difference between control and high dose group (P ≤ 0.05) |
1.460 ± 0.728 statistically significant difference between control and low dose group (P ≤ 0.05) |
1.320 ± 0.504 statistically significant difference between control and high dose group (P ≤ 0.05) |
Myelocyte | 3.540 ± 0.088 statistically significant difference between control and low dose group (P ≤ 0.05) |
2.180 ± 0.896 statistically significant difference between control and low dose group (P ≤ 0.05) statistically significant difference between low dose and high dose group (P ≤ 0.05) |
3.300 ± 1.600 statistically significant difference between low dose and high dose group (P ≤ 0.05) |
Metamyelocyte | 6.540 ± 1.208 statistically significant difference between control and low dose group (P ≤ 0.05) statistically significant difference between control and high dose group (P ≤ 0.05) |
3.840 ± 1.568 statistically significant difference between control and low dose group (P ≤ 0.05) statistically significant difference between low dose and high dose group (P ≤ 0.05) |
3.120 ± 1.824 statistically significant difference between control and high dose group (P ≤ 0.05) statistically significant difference between low dose and high dose group (P ≤ 0.05) |
Band neutrophils | 15.940 ± 2.872 statistically significant difference between control and low dose group (P ≤ 0.05) statistically significant difference between control and high dose group (P ≤ 0.05) |
8.620 ± 1.304 statistically significant difference between control and low dose group (P ≤ 0.05) statistically significant difference between low dose and high dose group (P ≤ 0.05) |
6.520 ± 1.944 statistically significant difference between control and high dose group (P ≤ 0.05) statistically significant difference between low dose and high dose group (P ≤ 0.05) |
Neutrophilic granulocytes | 12.460 ± 2.192 statistically significant difference between control and high dose group (P ≤ 0.05) |
10.920 ± 1.104 statistically significant difference between low dose and high dose group (P ≤ 0.05) |
18.680 ± 9.016 statistically significant difference between control and high dose group (P ≤ 0.05) statistically significant difference between low dose and high dose group (P ≤ 0.05) |
Eosinophilic myelocytes | 1.740 ± 0.456 | 1.180 ± 0.776 | 0.820 ± 0.384 |
Eosinophilic metamyelocytes | 2.220 ± 0.464 | 2.320 ± 1.464 | 0.840 ± 0.568 |
Band eosinophils | 2.960 ± 1.952 statistically significant difference between control and high dose group (P ≤ 0.05) |
3.300 ± 2.200 statistically significant difference between low dose and high dose group (P ≤ 0.05) |
1.420 ± 1.112 statistically significant difference between control and high dose group (P ≤ 0.05) statistically significant difference between low dose and high dose group (P ≤ 0.05) |
Eosinophilic granulocytes | 2.000 ± 1.480 statistically significant difference between control and low dose group (P ≤ 0.05) |
2.460 ± 1.632 statistically significant difference between control and low dose group (P ≤ 0.05) statistically significant difference between low dose and high dose group (P ≤ 0.05) |
2.120 ± 1.096 statistically significant difference between control and low dose group (P ≤ 0.05) statistically significant difference between low dose and high dose group (P ≤ 0.05) |
Basophilic myelocytes | 0.020 ± 0.032 | 0.000 | 0.000 |
Basophilic metamyelocytes | 0.080 ± 0.064 | 0.000 | 0.040 ± 0.048 |
Band basophiles | 0.260 ± 0.192 statistically significant difference between control and low dose group (P ≤ 0.05) statistically significant difference between control and high dose group (P ≤ 0.05) |
0.060 ± 0.072 statistically significant difference between control and low dose group (P ≤ 0.05) statistically significant difference between low dose and high dose group (P ≤ 0.05) |
1.420 ± 1.112 statistically significant difference between control and high dose group (P ≤ 0.05) statistically significant difference between low dose and high dose group (P ≤ 0.05) |
Basophilic granulocytes | 0.320 ± 0.184 statistically significant difference between control and low dose group (P ≤ 0.05) statistically significant difference between control and high dose group (P ≤ 0.05) |
0.040 ± 0.064 statistically significant difference between control and low dose group (P ≤ 0.05) statistically significant difference between low dose and high dose group (P ≤ 0.05) |
0.080 ± 0.064 statistically significant difference between control and high dose group (P ≤ 0.05) statistically significant difference between low dose and high dose group (P ≤ 0.05) |
Hypersegmented granulocytes | 0.000 statistically significant difference between control and high dose group (P ≤ 0.05) |
0.000 statistically significant difference between low dose and high dose group (P ≤ 0.05) |
0.500 ± 0.640 statistically significant difference between control and high dose group (P ≤ 0.05) statistically significant difference between low dose and high dose group (P ≤ 0.05) |
Total granulocytes | 52.860 ± 2.528 statistically significant difference between control and low dose group (P ≤ 0.05) statistically significant difference between control and high dose group (P ≤ 0.05) |
37.520 ± 8.784 statistically significant difference between control and low dose group (P ≤ 0.05) |
44.680 ± 3.144 statistically significant difference between control and high dose group (P ≤ 0.05) |
Expansion of knowledge on the impact of repeated exposure of human and animal organisms to acrylamide is paramount, especially in the aspect of interspecies differences in sensitivity to its toxic activity. The sparseness of research on its influence on haematopoiesis occurring in bone marrow prompted the authors of this publication to address this topic and model it in the domestic pig. Due to this species’ phylogenetic similarity to humans, it is often used as an animal model (25). However, most experiments on the effects of AA on mammals were conducted on rodents (4, 5, 19).
Since acrylamide is a compound widely distributed in the environment, most humans are exposed to it in varying amounts in food and other sources such as tobacco smoke (7). The WHO estimated that the total daily intake of AA from food ranges between 0.3 and 0.8 μg/kg b.w. (20). Livestock and pets are also at risk of its negative effects as inhabitants of the same environment as humans, and it could be assumed that daily exposure to AA in animals is similar to that in humans. However, considering humans’ consumption of a wide range of highly processed food, human exposure to acrylamide could be even higher, and its effect on bone marrow even more detrimental. Literature data indicate that besides damaging bone marrow, acrylamide toxicity can manifest in skeletal muscle atrophy, distended urinary bladders, increased prevalence of duct ectasia in preputial glands, haematopoietic cell proliferation in the spleen, hepatocyte degeneration and liver necrosis, mesenteric lymph node cellular infiltration and pituitary gland hyperplasia (23).
Research conducted by Dobrzyńska (4) on mice shows toxic AA activity by dose-dependent increase in DNA damage of somatic and germ cells. The results of the study by Benziane
Results regarding acrylamide administration published so far indicate bone marrow hyperplasia in rats (6). Developing anaemia and thrombopaenia as well as an increase in the number of leukocytes were observed in mice in research by Raju
A study by Hammad
The results obtained during the present investigation clearly show that acrylamide suppresses granulopoiesis, which manifests in a decreased number of most types of cells from the granulocytic cell line and changes in cell morphology. It was seen that different doses can have different effects on certain cell types. Moreover, the results of this research may be a valuable source of information about the harmfulness of acrylamide to the process of granulopoiesis in humans and animals, especially in view of the high utility of the domestic pig as a scientific model adopted for research applicable to humans.